Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Inserting the gene for interleukin-2 into a person's prostate cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of Leuvectin in treating patients who have locally recurrent prostate cancer after receiving treatment with radiation therapy.

Key facts

Study ID

NCT00005072

Run by

Vical

People needed

25

Starts

2000-11-01

Expected to finish

2003-04-01

Last updated by the study team

2014-07-29

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.